Friday, 13 November 2026European Markets

PROSAFE Stock Bullish Momentum With A 12.33% Rise Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with PROSAFE (PRS.OL) rising 12.33% to kr25.05 on Friday, following the last session's downward trend. Oslo Børs Benchmark Index_GI rose 0.93% to kr1,449.45, following the last session's downward trend on what was a somewhat bullish trend exchanging session today.

PROSAFE's last close was kr22.30, 74.52% below its 52-week high of kr87.52.

About PROSAFE

Prosafe SE, together with its subsidiaries, owns and operates semi-submersible accommodation vessels in South America, north America, and Europe. It is also involved in the maintenance and modification of installations on fields for the production, hook-up and commissioning of new fields, tiebacks to existing infrastructure, and decommissioning activities. The company owns and operates a fleet of six semi-submersible accommodation vessels and one tender support vessel. It primarily serves oil and gas industries. Prosafe SE was founded in 1972 and is headquartered in Stavanger, Norway.

Earnings Per Share

As for profitability, PROSAFE has a trailing twelve months EPS of kr-20.91.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -230.5%.

More news about PROSAFE (PRS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com